This perspective asks: What is biological intelligence? Why do we need biological intelligence to address today’s challenges in drug discovery? What are some of the opportunities in drug discovery for neurological disorders? What distinguishes BRAINCURES’ biological intelligence (BI) approach from today’s state of the art artificial intelligence (AI)? Who are BRAINCURES’ competitors? How can we work together?

What is biological intelligence?

Biological intelligence: a biology first approach that enables failure free drug discovery without deep learning steps associated with artificial intelligence (AI), an approach that has captured the interest of pharma, but is not yet trusted a lot (1) as most companies have not been in the game long enough to have generated molecules that reached late-stage clinical trials (2)

Why do we need biological intelligence to address today’s challenges in drug discovery?

Drug discovery is troubled by high failure rates where only 1 in 10 of drugs that have a proof of mechanism are making it to the market. This makes drug development a very risky and expensive business where most of the losses are caused by multiple preclinical- or costly Phase III- failures. Some of the challenges include:

  • traditional drug discovery processes take around 12 years, cost over 2.6 billion USD and carry a 4 % success rate (3)
  • drug discovery costs for neurological disorders such as Alzheimer’s disease (AD) are estimated at 5.6 billion USD due to a 99.6% attrition rate during the 2002 to 2012 period that has resulted in many pharmaceutical companies closing or scaling back their development programs (4)
  • there is a healthcare cost vs venture funding gap associated with psychiatric, addiction, pain and dementia as compared to funding dollars dedicated to cancer research, where lead stage programs in oncology have received 16 times more venture dollars as compared to programs in Alzheimer’s disease (5)

What are some of the opportunities in drug discovery for neurological disorders?

Some of the opportunities include:

  • the neurological disease market is an emerging investment opportunity as in 2016 neurological diseases generated over 75 billion USD in revenue for pharmaceutical manufacturers and is expected to reach 130.8 billion USD by 2025, expanding at a CAGR of 6.2% from 2017 to 2025 (6) 
  • computational methods to finding new treatments such as artificial intelligence (AI) are projected to reach 35.9 billion USD by 2025 at a CAGR of 57.2% (7). However, many of these methods are flawed and may not deliver what they promise (8).
  • BRAINCURES biological intelligence enables traditional- and AI-driven drug discovery to do more better as we’ve leveraged state of the art genomic technologies to decode the molecular programs behind how disease progress or regress. This allows us to deliver predictions that have a 100% preclinical and an least 60 to 100% clinical success rate (9)

What distinguishes BRAINCURES’ biological intelligence (BI) approach from today’s state of the art artificial intelligence (AI)?

To build the BRAINCURES Discovery Engine (BDE) we took a back to biology approach to discover improved mechanisms of action that will enable precision medicine. This has allowed us to decipher the molecular code behind health to disease transitions that enables increased success rates without deep learning/pattern discovery steps associated with AI. This allows the BDE to

  • bypass the need for big data and long training times to create a machine learning model
  • make predictions outside of the distribution of data it has already seen (unachievable with AI)
  • make predictions that are more customer-acceptable than purely statistical methods, as it uses a mechanistic model that exposes the way by which a drug is likely to fail or succeed rather than rely on AI’s ‘black box algorithm’ model, which lacks contextual proof. The BDE therefore aligns with the EU GDPR’s ‘right of explanation’ for customers when automated decision-making technology is used. AI’s ‘black box’ model is incompatible with GDPR regulations (10)

Who are BRAINCURES’ competitors?

BRAINCURES is the first declared biological intelligence company and it’s key competitors include a selection of 215 AI-driven companies (11).

Key advantages of selecting to work with BRAINCURES include:

  • We have a biology powered algorithm that in clearly benchmarked way can deliver at least 60% clinical success rates
  • We are one of the few data analytics with a primary declared interest neuroscience
  • We impact the full drug development life cycle, rather than just aspect of it (e.g., target identification, optimal compound design)

How can we work together?

To learn more about our biological intelligence approach we refer you to our introductory whitepaper entitled “Biological Intelligence: a new paradigm for informed and nearly failure free drug discovery” (12) or invite you to visit www.braincures.com to contact us to discuss how we can do better, safer and faster drug discovery together thanks to our molecular GPS-powered biological intelligence approach to precision medicine.

References

  1. Eric Smalley. AI-powered Drug Discovery Captures Pharma Interest, Nat Biotechnol. 2017; 35(7):604-605
  2. David H Freedman. Hunting for New Drugs With AI. Nature. 2019; 576(7787):S49-S53
  3. Cook et al., Nat Rev Drug Discov 2014 (13):419-431; Carter et al., Nat Rev Drug Discov 2016 (15):673-674
  4. Cummings et al., Alzheimers Res Ther 2014 6(4):37; Cummings et al., Alzheimers Dement 2018 4:330-343
  5. Thomas, D., Wessel, C. BIO Industry Analysis. Highly Prevalent Chronic Disease Volume IV: Alzheimer’s Disease Therapeutics, (2019)
  6. http://www.abnewswire.com/pressreleases/neurological-diseases-treatment-market-anticipated-for-progressive-cagr-growth-during-20172025-insights-shared-in-detailed-report_167205.html 
  7. https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-market
  8. Eric E Topol. Nat Med 2019 25(1):44-56
  9. Danny Sullivan. Move over AI? Here comes biological intelligence. 4 June 2020. https://www.longevity.technology/move-over-ai-here-comes-biological-intelligence/
  10. Guidotti R, Monreale A, Pedreschi D. The AI black box explanation problem. KDnuggets.com. March 2019 (19:n12). https://www.kdnuggets.com/2019/03/ai-black-box-explanation-problem.html [Accessed 1 July 2020]
  11. https://www.biopharmatrend.com/m/free-reports/ai/ [Accessed 1 July 2020]
  12. Krzysztof Potempa. Biological Intelligence: a new paradigm for informed and nearly failure free drug discovery. 12 February 2020 https://lnkd.in/dBdM-mZc5

Published By

Krzysztof Potempa

Dreamster dedicated to the prevention and treatment of mental health disorders that affect at least 1 in 10 people worldwide!

Follow

Biological intelligence: a new era in drug discovery